X0306 4 2019-08-26 0 0001679082 Myovant Sciences Ltd. MYOV 0001714080 Arjona Ferreira Juan Camilo C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY, 9TH FLOOR BRISBANE CA 94005 0 1 0 0 Chief Medical Officer Common Shares 2019-08-26 4 A 0 47570 0.00 A 57310 D Stock Option (Right to Buy) 10.60 2019-08-26 4 D 0 260000 0.00 D 2027-08-14 Common Shares 260000 0 D Stock Option (Right to Buy) 7.78 2019-08-26 4 A 0 260000 0.00 A 2027-08-14 Common Shares 260000 260000 D Stock Option (Right to Buy) 21.87 2019-08-26 4 D 0 87050 0.00 D 2028-04-15 Common Shares 87050 0 D Stock Option (Right to Buy) 7.78 2019-08-26 4 A 0 87050 0.00 A 2028-04-15 Common Shares 87050 87050 D Stock Option (Right to Buy) 24.44 2019-08-26 4 D 0 66130 0.00 D 2029-04-04 Common Shares 66130 0 D Stock Option (Right to Buy) 7.78 2019-08-26 4 A 0 66130 0.00 A 2029-04-04 Common Shares 66130 66130 D The Common Shares are to be acquired upon the vesting of certain Restricted Stock Units ("RSUs") granted to the Reporting Person. The RSUs shall vest as follows: (i) 1/3 of the total shares subject to the RSUs shall vest at the later occurrence of (a) the achievement of certain milestones and (b) the first anniversary of the grant date; and (ii) 2/3 of the total shares subject to the RSUs shall vest as follows: 1/8 vesting on the first anniversary of the grant date and 7/8 vesting in seven even installments each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. Each reported acquisition and disposition of an option for the like number of shares consisted of an amendment to an outstanding option, resulting in the deemed cancellation of the "old" option and grant of a replacement option. 1/4 of the common shares underlying this option vested on August 15, 2018, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. The replacement option provides that the Reporting Person cannot exercise the currently vested portion of the replacement option for 12 months commencing on August 26, 2019, subject to certain exceptions provided by the Reporting Person's applicable option agreement. 1/4 of the common shares underlying this option vested on April 16, 2019, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. The replacement option provides that the Reporting Person cannot exercise the currently vested portion of the replacement option for 12 months commencing on August 26, 2019, subject to certain exceptions provided by the Reporting Person's applicable option agreement. 1/4 of the common shares underlying this option vest on April 5, 2020, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. /s/ Matthew Lang, Attorney-in-fact 2019-08-27